

Representative Office Egis Pharmaceuticals PLC DISCLOSURE of payments to HCPs and HCOs 2025

Date of publication: 31 May 2026

	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier <i>OPTIONAL</i>	Donations and Grants to HCOs	Contribution to costs of Events			Fee for service and consultancy		TOTAL <i>OPTIONAL</i>	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
HCPs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
						N/A	N/A	N/A	N/A	N/A	N/A	N/A	
						N/A	N/A	N/A	N/A	N/A	N/A	N/A	
						N/A	N/A	N/A	N/A	N/A	N/A	N/A	
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients						N/A	N/A	Aggregate HCPs	Aggregate HCPs	11 983 441.01	Aggregate HCPs	11 983 441.01
Number of Recipients in aggregate disclosure						N/A	N/A	number	number	683	number	N/A	
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed						N/A	N/A	%	%	100%	%	N/A	
HCOs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
					N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
					N/A	N/A		N/A	N/A	N/A	N/A		
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients						Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	N/A
	Number of Recipients in aggregate disclosure						number	number	number	number	number	number	N/A
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed						%	%	%	%	%	%	N/A	
R & D	AGGREGATE DISCLOSURE												
	Transfers of Value re Research & Development as defined											N/A	N/A